Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Join Professor John Camm and Dr Stuart Connolly in their discussion of the full study publication of the ANNEXA-4 study: Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Register your email and provide your feedback

To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey

Highlights report

Coming soon!

Speaker

Dr Stuart Connolly

McMaster University

Ontario, Canada

Topic

The ANNEXA-4 trial is a multicentre, prospective, open-label, single-group study of andexanet alfa in patients with acute major bleeding. The study involved over 350 patients and evaluated both the efficacy and safety of andexanet alfa. This 30-minute journal club will explore the insights and impact of the full analysis of the published study ‘Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors’.

View abstract Access full paper

  • Target audience

    This educational activity is designed for hospitalists, haematologists, interventional cardiologists,
    internists/physicians, surgeons, and any other healthcare professional with an interest or role in the
    management of patients on anticoagulation with life-threatening bleeds.

  • Learning objectives

    After completing this educational activity, participants should be able to:

    • Describe the efficacy of andexanet alfa for the reversal of factor Xa inhibitors in patients
      presenting with factor Xa inhibitor associated bleeding
    • Recall the safety outcomes of andexanet alfa for the reversal of factor Xa inhibitors
  • Disclosures

    Prof John Camm

    • Advisor for: Boehringer Ingelheim, Daiichi Sankyo
    • Consultant (retained) for: Boehringer Ingelheim
    • Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer

    Dr Stuart Connolly

    • Major research grants, consulting fees and speaker fees from Sanofi-Aventis, Janssen, Pfizer,
      Bristol-Myers Squibb, Boehringer Ingelheim, Boston Scientific, Abbott, Bayer
      Pharmaceuticals Inc, Portola Pharmaceuticals, Medtronic, Daiichi Sankyo, Servier

    Staff and reviewer disclosures

    PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

  • Funding

    This independent educational activity is supported by funding from Portola Pharmaceuticals Inc.
    PCM Scientific is the medical education company acting as scientific secretariat and organiser for this
    programme. The activity is run independently of the financial supporter and all content is created by
    the faculty. No funder has had input into the content of the activity.